Quantum Biopharma (QNTM) Non Operating Investment Income (2019 - 2026)
Quantum Biopharma (QNTM) reported Non Operating Investment Income of $7.0 million for Q1 2026, up 123.6% on a YoY basis from $3.1 million in Q1 2025, and up 129.2% sequentially from -$23.8 million in Q4 2025.
Quantum Biopharma (QNTM) Non Operating Investment Income (2019 - 2026) Analysis & Trends
Quantum Biopharma (QNTM) has 7 years of Non Operating Investment Income data on file, last reported at $7.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Investment Income rose 123.6% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at -$8.1 million (down 349.06% YoY), and the FY2025 full-year result was -$11.9 million, down 11498.54% from the prior year.
- Non Operating Investment Income rose to $7.0 million in Q1 2026, from -$23.8 million in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $7.5 million in Q2 2025 to a low of -$23.8 million in Q4 2025.
- A 4-year average of -$574894.4 and a median of $67910.0 in 2024 frame the typical range for Non Operating Investment Income.
- Peak annual rise in Non Operating Investment Income reached 1690813.51% in 2025, while the deepest fall reached 17648.14% in 2025.
- Tracing QNTM's Non Operating Investment Income over 4 years: stood at -$898731.0 in 2022, then surged by 115.1% to $135746.0 in 2024, then sank by 17648.14% to -$23.8 million in 2025, then surged by 129.2% to $7.0 million in 2026.
- Business Quant data shows QNTM's Non Operating Investment Income at $7.0 million in Q1 2026, -$23.8 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Quantum Biopharma | 13.00 Bn | 13.00 Bn | - | 6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.95 Mn |
| Mar 31, 2026 | 6.95 Mn |
| Dec 31, 2025 | -23.82 Mn |
| Dec 31, 2025 | -23.82 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 7.55 Mn |
| Jun 30, 2025 | 7.55 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Dec 31, 2024 | 135,746.00 |
| Dec 31, 2024 | 135,746.00 |
| Sep 30, 2024 | 74.00 |
| Sep 30, 2024 | 74.00 |
| Jun 30, 2024 | -8,040.00 |
| Jun 30, 2024 | -8,040.00 |
| Mar 31, 2024 | -23,297.00 |
| Mar 31, 2024 | -23,297.00 |
| Dec 31, 2022 | -898,731.00 |
| Dec 31, 2022 | -898,731.00 |